Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after Resection

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Annals of Surgical Oncology

• Publication date

  2011-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1245/s10434-011-1610-xPMID 21360249
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey.

  2010cited by this paper
• Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma

  2009cited by this paper
• ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.

  2008cited by this paper
• Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

  2008cited by this paper
• ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.

  2008cited by this paper
• Platinum Resistance: The Role of DNA Repair Pathways

  2008cited by this paper
• Single Nucleotide Polymorphisms in Nucleotide Excision Repair Genes XPA, XPD, XPG and ERCC1 in Advanced Colorectal Cancer Patients Treated with First-Line Oxaliplatin/Fluoropyrimidine

  2008cited by this paper
• Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

  2007cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer

  2007cited by this paper
• Current status of excision repair cross complementing-group 1 (ERCC1) in cancer.

  2007cited by this paper
• Excision repair cross‐complementation group 1 predicts progression‐free and overall survival in non‐small cell lung cancer patients treated with platinum‐based chemotherapy

  2007cited by this paper
• Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

  2006cited by this paper
• Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

  2006cited by this paper
• Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

  2005cited by this paper
• A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

  2004cited by this paper
• A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

  2004cited by this paper
• Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma

  2002cited by this paper
• ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

  2001cited by this paper
• Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

  1999cited by this paper
• ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.

  1998cited by this paper
• A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues.

  1997cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper

• Genomic instability, DNA damage response and telomere homeostasis in pancreatic cancer.

  2025cites this paper
• Ribonucleotide reductase M2 subunit silencing suppresses tumorigenesis in pancreatic cancer via inactivation of PI3K/AKT/mTOR pathway.

  2022cites this paper
• Expression patterns and prognostic significances of RRM1 and ERCC1 in pancreatic carcinoma and cholangiocarcinoma

  2021cites this paper
• Cellular and molecular mechanisms of perineural invasion of pancreatic ductal adenocarcinoma

  2021cites this paper
• Necroptosis in head and neck squamous cell carcinoma: characterization of clinicopathological relevance and in vitro cell model

  2020cites this paper
• Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma

  2020cites this paper
• Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival.

  2020cites this paper
• The prognostic value of excision repair cross-complementing Group 1 expression in nasopharyngeal cancer patients

  2020cites this paper
• Isolation, characterization, and expansion of heterogeneous circulating tumor cell (CTC) populations from cancer patients using microfluidic technologies

  2019cites this paper
• Gene expression of excision repair cross-complementation group 1 enzyme as a novel predictive marker in patients receiving platinum-based chemotherapy in advanced bladder cancer

  2018cites this paper
• CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy

  2018cites this paper
• Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer.

  2018cites this paper
• A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma

  2017cites this paper
• Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer

  2017cites this paper
• The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.

  2017cites this paper
• Drug metabolism and pancreatic cancer

  2016cites this paper
• Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial

  2016cites this paper
• ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis

  2016cites this paper
• ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine

  2015cites this paper
• High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected pancreatic adenocarcinoma.

  2015cites this paper
• The Effects of HSP27 on Gemcitabine-Resistant Pancreatic Cancer Cell Line Through Snail

  2015cites this paper
• Predictive biomarkers for chemotherapies in pancreatic cancer

  2015cites this paper
• Prognostic Value of Excision Repair Cross-Complementing Gene 1, Dihydropyrimidine Dehydrogenase, and Human Equilibrative Nucleotide Transporter 1 Expression and Their Implications for Adjuvant Treatment in Patients With Ampullary Carcinoma

  2015cites this paper
• ERCC1 mRNA Expression as a Postoperative Prognostic Marker in Extrahepatic Bile Duct Cancer

  2014influential citation
• Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression

  2014cites this paper
• Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer

  2014cites this paper
• Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy

  2014cites this paper
• CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.

  2014cites this paper
• Opportunities for translation: targeting DNA repair pathways in pancreatic cancer.

  2014cites this paper
• Adjuvant therapy for resectable pancreatic adenocarcinoma: review of the current treatment approaches and future directions.

  2014cites this paper
• Influence of perineural invasion on survival and recurrence in patients with resected pancreatic cancer.

  2013cites this paper
• Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.

  2013cites this paper
• Pronecrotic mixed lineage kinase domain‐like protein expression is a prognostic biomarker in patients with early‐stage resected pancreatic adenocarcinoma

  2013cites this paper
• Important Roles of ERCC1 in DNA Repair and Targeted Therapy

  2013cites this paper
• An analysis of human equilibrative nucleoside transporter‐1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross‐complementing gene‐1 expression in patients with resected pancreas adenocarcinoma

  2013influential citation
• Reply to an analysis of human equilibrative nucleoside transporter‐1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross‐complementing gene‐1 expression in patients with resected pancreas adenocarcinoma: Implications for adjuvant treatment

  2013cites this paper
• Excision repair cross‐complementing gene‐1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter‐1 expression and prognostic value in biliary tract malignancy

  2013cites this paper
• Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma

  2013cites this paper
• Association of DNA Repair Gene Variants with Pancreatic Cancer in Patients with Chronic Pancreatitis

  2013cites this paper
• Endoscopy in Pancreatic Cancer: An Oncologist's Perspective

  2013cites this paper
• Adjuvant strategies for resectable pancreatic cancer: have we made progress?

  2012cites this paper
• Early Recurrence of Pancreatic Cancer after Resection and During Adjuvant Chemotherapy

  2012cites this paper
• Genomics and pharmacogenomics of pancreatic adenocarcinoma

  2011cites this paper
• THE PROGNOSTIC ROLE OF ERCC1 IN ADVANCED NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW & META-ANALYSIS

  2011cites this paper
• Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.

  2011cites this paper
• CDK 9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy

  year unknowncites this paper